Caught this move early pre-market and saw that it was failing due to 1Q loss and not winning on the news of their licensing deal to commercialize their "5aR Inhibitor CCX168 for orphan and rare diseases in major markets". I capitalized once I saw the quick consolidation at 3.50 and then jumped in to short. I got out quick (within 2 min) because you never know when these overall markets will flip this 2016 year. Should have held down to 3.00 at the end of the day, but this was a success! Study!